Webinars and Commercial Conversations — Register Now

Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.

Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers

Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Product Spotlight

Gold Standard Diagnostics

AIX1000 Agglutination Instrument

Company

Gold Standard Diagnostics

Name of instrument

AIX1000 Agglutination Instrument

Email

gsd.sales@us.goldstandarddiagnostics.com

City, State

Davis, CA

Phone

530-759-8000   

Website

https://clinical.goldstandarddiagnostics.com/us

Type of instrument

immunoassay

List price/First year sold in U.S.

—/2016

Targeted hospital bed size/Targeted test volume

—

Company manufactures instrument

yes (also sold by Cardinal Health, Thermo Fisher Scientific, VWR)

Other models in this family of analyzers

AIX1000 2.0, AIX1000 2.1

No. of units in clinical use in U.S./Outside U.S. (countries)

—

Dimensions (H × W × D)/Instrument footprint

17.7 × 25.2 × 22.5 in./4.1 sq. ft.

Weight empty/Weight fully loaded

62 lbs./~110 lbs.

No. of different measured assays onboard simultaneously

2 (2 can be run and calibrated at one time)

No. of user-definable (open chemistry) channels

—

Test throughput per hour/Assay run time

128 (128 tests in throughput)/75 min.

No. of direct ion-selective electrode channels

—

Detection methods

—

Stat time until completion/specimen throughput for Ion-selective electrode

—

Stat time until completion/specimen throughput for Ion-selective electrode basic metabolic panel

—

Stat time until completion/specimen throughput for Ion-selective electrode complete metabolic panel

—

Typical time delay from ordering stat test until aspiration of sample

—

Fully automated microplate immunoassay system

no

Methodologies supported

agglutination

Separation methodologies

none necessary

Stat time until completion of a ß-hCG test

—

Stat time until completion of a cTn test

—

• Typical time delay from test order to aspiration of sample

—

Reagents refrigerated onboard/Reagents ready to use

no/—

Reagent lot tracking/Reagent inventory

no/no

Reagent form/Reagents barcoded

liquid chemistry (closed reagent system)/yes

Separate reagent pack for each specimen/for each test run

no/no

Walkaway capability/Walkaway duration

yes/20–90 min. 

Design of sample-handling system

universal slide-in racks

Uses washable cuvettes/Uses disposable cuvettes

no/no

Min.–max. sample volume that can be aspirated at one time 

1–150 µL

Min. reaction volume/Min. specimen volume/Min. dead volume

105 µL/300 µL/150 µL

Dedicated pediatric sample cup

no

Primary tube sampling

yes

Accommodates most standard tube sizes/Accepts nonstandard tube sizes

yes/yes (12–16 × up to 100 mm)

Pierces caps on primary tubes

no

Protects against probe collision

yes

Detects clots/liquid level/short sample

no/yes/yes

Detection or quantitation for hemolysis, icterus, lipemia, clots

hemolysis, icterus, lipemia, clots not available 

Dilutes patient samples onboard/Susceptibility to carryover

yes/—

Automatic rerun capability

yes

Sample volume can be diluted to rerun out-of-linear-range high results

no

Sample volume can be concentrated to rerun out-of-linear-range low results

no

Autocalibration/Multipoint calibration supported

—

Typical calibration frequency for ISE/therapeutic drugs/drugs of abuse/general chemistries/immunoassays

—

Automatic programmable start/Automatic programmable shutdown

no (< 5 min. start-up time)/no

Onboard real-time QC/Onboard software capability to review QC

yes/yes

Supports multiple QC lot numbers per analyte

no

Waste management

manually by user

Sample barcode-reading capability/Autodiscrimination

yes (Interleaved 2 of 5, UPC, Codabar, Code 39, Code 128, 1D, 2D)/yes

Lab can control analyzer from remote computer

yes

Instrument can diagnose its own malfunctions

yes (operator intervention required to order parts)

System malfunctions can be diagnosed via remote monitoring

yes

UPS backup power supply

no

Data-management capability/LIS or EHR systems interfaced

onboard/—

LIS interface provided/Bidirectional interface capability

yes/yes

Modem servicing provided/Service engineer on-site response time

—

Mean time between failures

— (displays error codes for troubleshooting)

Average scheduled maintenance time by lab personnel

daily: < 5 min.; weekly: < 20 min.; monthly: < 5 min.

Maintenance records kept onboard for user/vendor

yes/yes 

Maintenance training demonstration module onboard

no

Training included with purchase/Avg. time for basic user training

yes (minimum 1 training slot)/2 days (at customer site or online)

Advanced operator training/Extra charge for follow-up or advanced training

yes/—

Warranty provided/Cost of annual service contract (24 h/7 d)

yes (1 year)/—

Distinguishing features (supplied by company)

extra high titer capability on 2.1 model; run screens and titers out to 1:2048; universal slide-in racks accommodate a variety of tube sizes for easier and faster sample loading; automated processing, analysis, interpretation, and result and image archiving; 90 min. walkaway time for 192 specimens

More products
in this guide

Alinity ci-series
ASI Evolution RPR Syphilis Analyzer
DxI 9000 Access Immunoassay Analyzer
Pictus 700 (P700)
Agility Automated ELISA System
Yumizen C1200
Yumizen C560
VITROS 3600 Immunodiagnostic System
VITROS 4600 Chemistry System
VITROS XT 7600 Integrated System
cobas pro integrated solutions
IMMULITE 2000 XPi Immunoassay System
Phadia 250 Laboratory System
B⋅R⋅A⋅H⋅M⋅S KRYPTOR GOLD
QUANTA-Lyser 3000